SCHEMBL5872840

SCHEMBL5872840

Cc1cc(I)ccc1Nc1c(C(=O)NCc2cccnc2)cc(C(=O)O)c(F)c1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.50
SORT1 Q99523 1/20 0.50
NPSR1 Q6W5P4 1/20 0.46
KMT2A Q03164 4/20 0.45
ALDH1A1 P00352 4/20 0.45
MEN1 O00255 2/20 0.45
KDM4E B2RXH2 2/20 0.45
PKM P14618 1/20 0.45
MAPT P10636 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
TSHR P16473 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
RECQL P46063 1/20 0.44
HTT P42858 2/20 0.44
HSD17B10 Q99714 2/20 0.44
LMNA P02545 2/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5872838 0.96 USP2 (0.50) USP2SORT1NPSR1KMT2AALDH1A1
SCHEMBL5872768 0.85 SORT1 (0.47) SORT1KMT2AMEN1TDP1HTT
SCHEMBL5873059 0.84 SORT1 (0.47) SORT1KMT2AALDH1A1MEN1TDP1
SCHEMBL5873057 0.81 SORT1 (0.47) SORT1KMT2AALDH1A1MEN1TDP1
SCHEMBL5872861 0.80 MEN1 (0.53) KMT2AMEN1TDP1SMN1; SMN2
SCHEMBL5872850 0.79 MAP2K1 (0.56) KMT2AMEN1TDP1SMN1; SMN2
SCHEMBL5872817 0.78 SMN1; SMN2 (0.44) SORT1KMT2AALDH1A1MEN1KDM4E
SCHEMBL6035831 0.78 KMT2A (0.47) SORT1KMT2AALDH1A1MEN1KDM4E
SCHEMBL6260604 0.78 HDAC8 (0.48) KMT2AALDH1A1MEN1KDM4EPKM
SCHEMBL5379244 0.77 MEN1 (0.53) KMT2AMEN1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7001905-B2 Substituted diarylamines as MEK inhibitors WARNER-LAMBERT COMPANY (US) 2006-02-21 US disclosed
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors BIWERSI CATHLIN (US) 2003-12-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225076-A1 5-Amide substituted diarylamines as mex inhibitors NRAS, MAPK6, MAPK12 USP2 4601/4885SORT1 4712/4885NPSR1 1867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.